- Home
- DTIL vs CUE Comparison
DTIL vs CUE Comparison
Compare DTIL & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTIL | CUE |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 27.1M |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | DTIL | CUE |
|---|---|---|
| Price | $4.75 | $0.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $60.00 | $3.00 |
| AVG Volume (30 Days) | 158.4K | ★ 316.8K |
| Earning Date | 03-31-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 106.52 | 35.14 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000,000.00 | $9,287,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $34.30 | $25.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 69.16 |
| 52 Week Low | $3.53 | $0.23 |
| 52 Week High | $8.82 | $1.12 |
Technical Indicators
Market Signals| Indicator | DTIL | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 63.59 | 47.64 |
| Support Level | $4.66 | $0.29 |
| Resistance Level | $5.19 | $0.36 |
| Average True Range (ATR) | 0.28 | 0.02 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 76.34 | 73.35 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.